| __timestamp | Taro Pharmaceutical Industries Ltd. | Viridian Therapeutics, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 91733000 | 7751000 |
| Thursday, January 1, 2015 | 87644000 | 10251000 |
| Friday, January 1, 2016 | 92365000 | 9575000 |
| Sunday, January 1, 2017 | 85656000 | 10912000 |
| Monday, January 1, 2018 | 88196000 | 11049000 |
| Tuesday, January 1, 2019 | 89971000 | 11646000 |
| Wednesday, January 1, 2020 | 93413000 | 13265000 |
| Friday, January 1, 2021 | 91355000 | 25805000 |
| Saturday, January 1, 2022 | 113676000 | 35182000 |
| Sunday, January 1, 2023 | 198366000 | 94999000 |
| Monday, January 1, 2024 | 218935000 |
In pursuit of knowledge
In the competitive world of pharmaceuticals, managing Selling, General, and Administrative (SG&A) expenses is crucial for profitability. Taro Pharmaceutical Industries Ltd. and Viridian Therapeutics, Inc. offer a fascinating study in contrasts. Over the past decade, Taro has consistently maintained higher SG&A expenses, peaking in 2024 with a 138% increase from 2014. In contrast, Viridian's SG&A costs have shown a more volatile pattern, with a significant surge in 2023, marking a 1,125% increase from 2014. This dramatic rise suggests aggressive expansion or restructuring efforts. While Taro's steady increase reflects a more controlled approach, Viridian's fluctuating expenses indicate a dynamic strategy. Missing data for 2024 suggests ongoing developments. As these companies navigate the complexities of the pharmaceutical industry, their SG&A strategies will be pivotal in determining their financial health and competitive edge.
Breaking Down SG&A Expenses: GSK plc vs Viridian Therapeutics, Inc.
Operational Costs Compared: SG&A Analysis of argenx SE and Viridian Therapeutics, Inc.
United Therapeutics Corporation or Taro Pharmaceutical Industries Ltd.: Who Manages SG&A Costs Better?
Operational Costs Compared: SG&A Analysis of Insmed Incorporated and Viridian Therapeutics, Inc.
Selling, General, and Administrative Costs: Bio-Techne Corporation vs Viridian Therapeutics, Inc.
Cost Management Insights: SG&A Expenses for Catalent, Inc. and Taro Pharmaceutical Industries Ltd.
Cost Management Insights: SG&A Expenses for Perrigo Company plc and Viridian Therapeutics, Inc.
Xenon Pharmaceuticals Inc. or Viridian Therapeutics, Inc.: Who Manages SG&A Costs Better?
Amphastar Pharmaceuticals, Inc. and Viridian Therapeutics, Inc.: SG&A Spending Patterns Compared
Taro Pharmaceutical Industries Ltd. or Viridian Therapeutics, Inc.: Who Invests More in Innovation?
Taro Pharmaceutical Industries Ltd. or Travere Therapeutics, Inc.: Who Manages SG&A Costs Better?
Xencor, Inc. and Viridian Therapeutics, Inc.: SG&A Spending Patterns Compared